This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Feb. 4, 2011 /PRNewswire/ -- Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused in dermatology and cancer, today announced positive results from its consumer trial with Allumera™, a breakthrough cosmetic treatment formulated to improve the skin's appearance.
The RevitAll study was performed with a standard cosmetic protocol and designed to confirm if treatment with Allumera™ improves skin appearance, when compared to exposure by light alone. The study also looked into longevity of results.
This controlled, prospective study enrolled 120 women to receive three treatments, four weeks apart.
The total duration of the study was five months. Half the study participants received Allumera™ plus light, while the remaining received light alone (control group). Participants were monitored for three months following the last treatment to evaluate which effects were long-lasting. The study evaluations included both objective and subjective assessments. The objective assessments included measurement of pores, skin firmness/elasticity, skin tone (radiance/luminosity), skin surface topography and tolerability.
At the five month evaluation, participants who received Allumera™ for one hour followed by exposure to light, showed a significant 44% reduction in the appearance of pores (p<0.001), when compared to baseline, and the difference between the two groups was statistically significant (p=0.002). A statistically significant improvement (p<0.0001) in skin firmness and suppleness was also observed for the Allumera group when compared to the control group. A 35% improvement in the appearance of skin tone (p<0.05) was also found, but this, however, was not statistically significant when compared to the control group.
"The results from our RevitAll study provide a solid foundation for our efforts to commercialize Allumera™," said Kjetil Hestdal, M.D. Ph.D., President and Chief Executive Officer of Photocure. "It is a significant milestone for our Photocure Technology™ and provides validation for our technology in cosmetic dermatology aimed at improving the skin's appearance. The upcoming launch of Allumera™ is a major step forward in establishing Photocure's US business."